Significant tumor growth inhibition (TGI) was observed over 24 days in animals with tumors derived from cells harboring PRMT1-targeting shRNA and treated with doxycycline compared to control groups (PRMT1 sh1 + Dox versus NT shRNA + Dox: percentage of tumor growth inhibition (% TGI) = 68, ***p < 0.001; PRMT1 sh1—Dox versus PRMT1 sh1 + Dox: %TGI = 70, ***p < 0.001) (Fig. 1f and Supplementary Fig. 6a). This evidence concerns the gene PRMT1 and neoplasm.